We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Imara Inc. (the "Company") (Nasdaq: IMRA) today announced that it has commenced a proposed underwritten public offering of $50 million of shares of its common stock. All of the shares are being offered by the Company.
Imara announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IMR-687, the company’s lead product candidate for the treatment of sickle cell disease.